NCT04001569: AZD8186 and Paclitaxel in Advanced Solid Tumors

NCT04001569
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Ph+ase 1b
Exclusions: Patients with active unstable central nervous system (CNS) lesions- see trial for details
https://ClinicalTrials.gov/show/NCT04001569

Comments are closed.

Up ↑